Treatment of Digoxin Toxicity
Administer digoxin-specific antibody fragments (digoxin-Fab) immediately for life-threatening digoxin toxicity, which is the definitive treatment with 50-90% response rates and dysrhythmia resolution typically within 30-45 minutes 1.
Primary Treatment: Digoxin-Fab
The 2023 American Heart Association guidelines provide a Class 1 recommendation (strongest level) for digoxin-Fab administration in digoxin or digitoxin poisoning 1. This is the cornerstone of management and should not be delayed when life-threatening toxicity is present.
Indications for Digoxin-Fab:
Life-threatening manifestations requiring immediate treatment:
- Ventricular tachycardia or ventricular fibrillation
- Progressive bradyarrhythmias or heart block
- Serum potassium >5.0-5.5 mEq/L in acute overdose
- Ingestion >10 mg in adults or >4 mg in children
- Steady-state serum digoxin concentration >10 ng/mL
- Hemodynamic instability 2
Important clinical caveat: Digoxin toxicity can occur even with therapeutic serum levels (0.8-2.0 ng/mL), particularly in the presence of hypokalemia, hypomagnesemia, or renal impairment 3, 4. Clinical features trump laboratory values—if the patient exhibits signs of severe toxicity with therapeutic levels, treat with digoxin-Fab anyway.
Initial Stabilization Steps
Before or while arranging digoxin-Fab:
Discontinue digoxin immediately 2
Correct electrolyte abnormalities:
- Maintain potassium between 4.0-5.5 mmol/L if hypokalemic
- Correct hypomagnesemia
- Critical warning: Do NOT give potassium if bradycardia, heart block, or massive overdose is present—this can be lethal 2
- In massive overdose with hyperkalemia, avoid potassium supplementation entirely; the hyperkalemia will resolve with digoxin-Fab 2
Gastrointestinal decontamination (if acute ingestion <2 hours):
- Activated charcoal in large doses
- Consider gastric lavage only if <30 minutes post-ingestion
- Do not induce emesis if patient is obtunded or if >2 hours post-ingestion (risk of vagal stimulation worsening arrhythmias) 2
Management of Specific Arrhythmias
Bradyarrhythmias/Heart Block:
Primary approach: Digoxin-Fab is first-line 1
Temporizing measures while awaiting digoxin-Fab:
- Atropine may be reasonable (Class 2b recommendation) 1, 2
- Temporary transvenous pacing may be reasonable but has 36% complication rate and may require higher-than-normal current 1
- Asymptomatic bradycardia may only require drug withdrawal and monitoring 2
Ventricular Arrhythmias:
Primary approach: Digoxin-Fab 1, 2
Temporizing antiarrhythmics until digoxin-Fab available (Class 2b):
- Lidocaine
- Phenytoin
- Bretylium 1
What NOT to Do
The following are NOT recommended (Class 3: No Benefit):
- Hemodialysis
- Hemofiltration
- Hemoperfusion
- Plasmapheresis 1
Exception: One case report suggests continuous venovenous hemodialysis (CVVHD) may help when digoxin-Fab is unavailable and severe renal dysfunction is present 5, but this contradicts guideline recommendations and should only be considered in extraordinary circumstances.
Avoid calcium administration: Calcium given IV, particularly rapidly, can produce serious arrhythmias in digitalized patients 2
Monitoring and Post-Treatment
- Monitor ECG continuously
- Serial potassium levels (hyperkalemia in acute overdose resolves with digoxin-Fab; hypokalemia in chronic toxicity needs correction)
- Continue monitoring after digoxin-Fab administration for potential rebound toxicity (small risk) 4
- Reassess renal function, as impaired clearance is a major contributor to chronic toxicity 2
Key Clinical Pitfalls
Waiting for serum digoxin levels to guide treatment: Don't delay digoxin-Fab if clinical features suggest life-threatening toxicity 3, 6
Giving potassium in the wrong scenario: Potassium is dangerous in bradycardia, heart block, or massive overdose with hyperkalemia 2
Attempting cardioversion without addressing toxicity first: Reduce digoxin dose 1-2 days before elective cardioversion; use lowest energy if cardioversion cannot be delayed 2
Underestimating risk in elderly or renally impaired patients: These patients are at highest risk for chronic toxicity even at "therapeutic" levels 2, 7